Identification Keratin 1 as a cDDP-resistant protein in nasopharyngeal carcinoma cell lines

Journal of Proteomics

Volumn 75, Issue 8, 2012, Pages 2352-2360

  Tang, Sanyuan ^a,b   Huang, Weiguo ^b   Zhong, Meizuo ^a   Yin, Leilan ^a   Jiang, Hao ^a   Hou, Suping ^b   Gan, PingPing ^a   Yuan, Yujuan ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c Beijing Proteome Research Center   (China)

Author keywords

2 DE; CDDP; ESI Q TOF MS; KRT1; MDR; NPC

Indexed keywords

CARBOPLATIN; CATHEPSIN D; CISPLATIN; CYTOKERATIN 1; DOCETAXEL; FLUOROURACIL; LIPOCORTIN 5; SMALL INTERFERING RNA; VINCRISTINE;

ARTICLE; DOWN REGULATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TUMOR CELL; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATIN-1; MASS SPECTROMETRY; NASOPHARYNGEAL NEOPLASMS; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 84862791135     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.02.003     Document Type: Article

References (30)

1. Haddock R.L., Whippy H.J., Talon R.J., Montano M.V. Ethnic disparities in cancer incidence among residents of Guam. Asian Pac J Cancer Prev 2009, 10(1):57-62.
2. Corry J., Fisher R., Rischin D., Peters L.J. Relapse patterns in WHO 2/3 nasopharyngeal cancer: is there a difference between ethnic Asian vs. non-Asian patients?. Int J Radiat Oncol Biol Phys 2006, 64(1):63-71.
3. Li L.L., Shu X.S., Wang Z.H., Cao Y., Tao Q. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. Chin J Cancer 2011, 30(4):231-239.
4. Zhou L., Feng X., Shan W., Zhou W., Liu W., Wang L., et al. Epigenetic and genetic alterations of the EDNRB gene in nasopharyngeal carcinoma. Oncology 2007, 72(5-6):357-363.
5. Peng X., Li W., Tan G. Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression. Anticancer Drugs 2010, 21(4):381-388.
6. Ma B.B., Hui E.P., Wong S.C., Tung S.Y., Yuen K.K., King A., et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma-correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol 2009, 20(11):1854-1859.
7. Shekhar M.P. Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets 2011, 11(5):613-623.
8. Zhang S., Huang W.C., Li P., Guo H., Poh S.B., Brady S.W., et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011, 17(4):461-469.
9. Fallica B., Makin G., Zaman M.H. Bioengineering approaches to study multidrug resistance in tumor cells. Integr Biol (Camb) 2011, 3(5):529-539.
10. Oshikata A., Matsushita T., Ueoka R. Enhancement of drug efflux activity via MDR1 protein by spheroid culture of human hepatic cancer cells. J Biosci Bioeng 2011, 111(5):590-593.
11. Chandra H., Reddy P.J., Srivastava S. Protein microarrays and novel detection platforms. Expert Rev Proteomics 2011, 8(1):61-79.
12. Cecconi D., Palmieri M., Donadelli M. Proteomics in pancreatic cancer research. Proteomics 2011, 11(4):816-828.
13. Song Y., Yang J., Bai W.L., Ji W.Y. Antitumor and immunoregulatory effects of astragalus on nasopharyngeal carcinoma in vivo and in vitro. Phytother Res 2011, 25(6):909-915.
14. Chow B.H., Chua D.T., Sham J.S., Zhang M.Y., Chow L.W., Bi J., et al. Increased expression of annexin I is associated with drug-resistance in nasopharyngeal carcinoma and other solid tumors. Proteomics Clin Appl 2009, 3(6):654-662.
15. Lee A.J., Endesfelder D., Rowan A.J., Walther A., Birkbak N.J., Futreal P.A., et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011, 71(5):1858-1870.
16. Moitra K., Lou H., Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 2011, 89(4):491-502.
17. Zavascki A.P., Carvalhaes C.G., Picão R.C., Gales A.C. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010, 8(1):71-93.
18. Drain S., Catherwood M.A., Alexander H.D. Multidrug resistance in the chronic lymphoproliferative disorders. Leuk Lymphoma 2010, 51(10):1793-1804.
19. He Q., Zhang G., Hou D., Leng A., Xu M., Peng J., et al. Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. Oncol Rep 2011, 25(1):237-243.
20. Zhang Y.F., Li X.H., Shi Y.Q., Wu Y.Y., Li N., He Q., et al. CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53. Oncol Rep 2011, 25(4):1091-1098.
21. Zhang Y., Wang H., Wei L., Li G., Yu J., Gao Y., et al. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Breast Cancer Res Treat 2010, 123(3):679-689.
22. Yu S.T., Chen T.M., Chern J.W., Tseng S.Y., Chen Y.H. Downregulation of GSTpi expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH2-terminal kinase-mediated apoptosis. Anticancer Drugs 2009, 20(5):382-388.
23. Chu C., Su L.H., Chu C.H., Baucheron S., Cloeckaert A., Chiu C.H. Resistance to fluoroquinolones linked to gyrA and par C mutations and overexpression of acr AB efflux pump in Salmonella enterica serotype Choleraesuis. Microb Drug Resist 2005, 11(3):248-253.
24. Castellini M.A., Buguliskis J.S., Casta L.J., Butz C.E., Clark A.B., Kunkel T.A., et al. Malaria drug resistance is associated with defective DNA mismatch repair. Mol Biochem Parasitol 2011, 177(2):143-147.
25. MacDonald-Jankowski D.S. Keratocystic odontogenic tumour: systematic review. Dentomaxillofac Radiol 2011, 40(1):1-23.
26. Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 2011, 30(2):127-138.
27. Reichelt J., Furstenberger G., Magin T.M. Loss of keratin 10 leads to mitogen-activated protein kinase (MAPK) activation, increased keratinocyte turnover, and decreased tumor formation in mice. J Invest Dermatol 2004, 123(5):973-981.
28. Zhu S., Oh H.S., Shim M., Sterneck E., Johnson P.F., Smart R.C. C/EBPbeta modulates the early events of keratinocyte differentiation involving growth arrest and keratin 1 and keratin 10 expression. Mol Cell Biol 1999, 19(10):7181-7190.
29. Bai Y., Edamatsu H., Maeda S., Saito H., Suzuki N., Satoh T., et al. Crucial role of phospholipase Cepsilon in chemical carcinogen-induced skin tumor development. Cancer Res 2004, 64(24):8808-8810.
30. Remotti F., Fetsch J.F., Miettinen M. Keratin 1 expression in endothelia and mesenchymal tumors: an immunohistochemical analysis of normal and neoplastic tissues. Hum Pathol 2001, 32(8):873-879.